A novel method of bedside hyperthermic intraperitoneal chemotherapy as adjuvant therapy for stage-III gastric cancer

Figures & data

Table 1. Parameters for HIPEC.

HIPEC parameters	Setting
Duration (min)	60 min
Temperature (°C)
Input	41–43 °C
Output	40–42 °C
Rate of flow	180–200 ml/min
Dose of cisplatin in total	60 mg/m^2
Dose of normal saline / perfusion	2000–4000 ml

Figure 1. Schematic illustration of patient enrollment.

Table 2. Demographic characteristics of the participants.

	HIPEC group (N = 57)	Control group (N = 57)	P
Age (years, range)	56.6(46.4–66.8)	56.7(45.5–67.9)	0.958
Gender
Male (n, %)	46 (80.7%)	38 (66.7%)	0.136
Female (n, %)	11 (19.3%)	19 (33.3%)
ECOG performance status (n, %)
0	30 (52.6%)	28 (49.1%)	0.852
1	27 (47.4%)	29 (50.9%)
BMI (kg/m^2) Site (n, %)	22 (16–26)	23 (17–27)	0.910
Cardia of stomach	16 (28.1%)	17 (29.8%)	0.914
Fundus of stomach	8 (14.0%)	7 (12.3%)
Body of stomach	21 (36.8%)	23 (40.3%)
Pylorus of stomach	12 (21.1%)	9 (15.8%)
Total stomach	0	1 (1.8%)
Histopathology (n, %)
Adenocarcinoma (poor or moderately differentiated)	48 (84.2%)	46 (80.7%)	0.806
Adenocarcinoma (mucinous, signet cell or other type)	9 (15.8%)	11 (19.3%)
Tumor stage (n, %)*
IIIA	10 (17.5%)	21 (36.8%)	0.018
pT4aN1/pT3N2/pT2N3	7/2/1	20/0/1
IIIB	20 (35.1%)	9 (15.8%)
pT4bN1/pT4aN2/pT3N3	2/12/6	1/5/3
IIIC	27 (47.4%)	27 (47.4%)
pT4bN2/pT4aN3/pT4bN3	1/21/5	3/21/3

ECOG: Eastern Cooperative Oncology Group; * AJCC 7th.

Table 3. Treatment cycles.

	Mean cycles (range)	Std. Deviation	p Value
HIPEC group (N = 57)	5.9	2.0	0.959
Control group (N = 57)	5.9	1.7

Figure 2. Kaplan–Meier plot of disease-free survival (Panel A) and overall survival (Panel B) for the patients.

Table 4. Comparison of adverse events in the two groups.

	All grades			≥ 3grades
	HIEPC (N = 57)	Control (N = 57)	P	HIPEC (N = 57)	Control (N = 57)	p Value
Nausea/Vomiting	35 (61.4%)	30 (52.6%)	0.449	4 (7.0%)	4 (7.0%)	1.000
Diarrhea	17 (29.8%)	13 (22.8%)	0.524	2 (3.5%)	1 (1.8%)	1.000
Leukopenia	44 (77.2%)	52 (91.2%)	0.070	8 (14.0%)	9 (15.8%)	1.000
Thrombocytopenia	21 (36.8%)	49 (86.0%)	0.000	4 (7.0%)	4 (7.0%)	1.000
Fatigue	14 (25%)	12 (21.1%)	0.824	1 (1.8%)	0 (0.0%)	1.000
Renal toxicity	0 (0.0%)	1 (1.8%)	1.000	0 (0.0%)	1 (1.8%)	1.000
Liver dysfunction	4 (7.0%)	5 (8.8%)	1.000	0 (0.0%)	0 (0.0%)	1.000

Table 5. HIPEC-associated side effects.

	Patients (N = 57)
Pain at puncture point	2 (3.5 %)
Infection of puncture point	0 (0.0%)
Peritoneal inflammation	1 (1.8 %)
Intestinal perforation	0 (0.0%)
Bowel obstruction	0 (0.0%)
Perfusion failure	0 (0.0%)

Data availability statement

All data generated in this study were included in this published article.